MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib

The third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI–treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its un...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Nishiyama, Akihiro, Takeuchi, Shinji, Adachi, Yuta, Otani, Sakiko, Tanimoto, Azusa, Sasaki, Motoko, Matsumoto, Shingo, Goto, Koichi, Yano, Seiji
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Drug Discovery and Delivery
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540985/
https://ncbi.nlm.nih.gov/pubmed/32735723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14593
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge